blood-brain barrier (BBB) because of the attachment of butylbromide, preventing central adverse effects such as blurred vision and facial flushing with the use of this peripheral anticholinergic. 8 Butylscopolamine has a high affinity for muscarinic receptors located on the smooth-muscle cells of the gastrointestinal (GI) tract 8 and its efficacy in treating CRBD has not yet been reported. This study, therefore, evaluated the efficacy and tolerability of butylscopolamine in the treatment of CRBD in male patients undergoing urinary bladder catheterization.
Methods
This prospective, randomized, double-blind, and placebocontrolled study was performed after approval from the Institutional Review Board of Seoul National University Bundang Hospital (No. B-1201-070-002). During the preoperative visit, informed consents were provided by all patients and patients were educated about the CRBD (characterized as a burning sensation with an urge to void or discomfort in the supra-pubic area) and numerical rating scale (NRS). The protocol of this clinical trial was registered in the Clinical Research information Service (KCT 0000380). From February to November 2012, male patients (18-70 yr) with an ASA physical status I and II, who were to undergo elective urologic surgery for the upper urinary tract or robotic retropubic radical prostatectomy, were included. The patients required intraoperative catheterization of the urinary bladder and complained of CRBD after operation. Patients with a history of bladder outflow obstruction, prostate hyperplasia, overactive bladder (frequency: more than three times during the night or more than eight times in 24 h), neurogenic bladder, end-stage renal disease (serum creatinine .1.6 mg dl
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), morbid obesity, disturbances of the central nervous system (CNS), chronic analgesic abuse, and hepatic or psychiatric disease were excluded from the study.
All patients were premedicated with i. After reporting CRBD, patients were randomized into two groups using sealed envelopes by an anaesthesiologist responsible for the randomization. The control group received the same volume (1 ml) of normal saline whereas the butylscopolamine group received butylscopolamine 20 mg (Buscopan w , Boehringer Ingelheim Korea, Seoul, South Korea) i.v. All medications were prepared by an anaesthetic nurse blinded to the study and administered in identical 2 ml syringes.
The primary outcome was defined as the reduction in the severity of CRBD. Secondary outcomes were the requirement of rescue analgesic, heart rates (HRs), mean arterial pressure (MAP), and adverse effects including PONV, sedation, dry mouth, facial flushing, and blurred vision. All these outcomes except HR and MAP were assessed at baseline (when the patient complained of CRBD), 20 min, and 1, 2, and 6 h after administration of the study drug by blinded assessors. During each evaluation, patients were asked to specify whether the pain was related to CRBD or to the surgical wound. HR and MAP were recorded at 5, 10, and 20 min and 1 h after administration of the study drugs. The incidences of tachycardia (HR≥100 bpm) and hypertension (systolic/diastolic arterial pressure ≥140/90 mm Hg) during the study period were also recorded.
Severity of CRBD was recorded using an NRS ranging from 0 (no discomfort) to 100 (most severe discomfort). The rescue analgesic (fentanyl 50 mg) was administered when the postoperative pain NRS (0¼no pain, 100¼most severe pain) was .30 despite the PCA and the amount of rescue analgesics needed during the study period was recorded. The incidence of PONV and the need for rescue antiemetics were also assessed. Other adverse effects including dry mouth, facial flushing, and blurred vision were also observed. Sedation was evaluated using a modified observer's assessment of alertness/sedation score 9 at baseline, 20 min and 1 h after administration of the study drug. The calculation of the sample size was based on preliminary results. The severity of CRBD (NRS) of 10 patients was 75 (25) at the time of reporting CRBD. Assuming that the severity of CRBD reduced from 75 to 55 (decrease of 20) after therapy with butylscopolamine, 26 patients in each group were required for results to be statistically significant (with a¼0.05 and power¼0.80). To allow for a 10% dropout rate, 29 patients per group were included. SPSS ver. 15.0 (SPSS, Inc., Chicago, IL, USA) was used for statistical analysis. The severity of CRBD (NRS), HR and MAP over time between the groups were analysed by repeatedmeasures analysis of variance (ANOVA) and then t-test was used to compare values at each time point. Analyses of categorical variables (rescue analgesics, incidence of PONV, dry mouth, facial flushing, and blurred vision) were performed by x 2 or Fisher's exact-tests. Data were analysed according to the intention-to-treat principle. P,0.05 was considered to indicate significance.
Results
Eighty-two patients were recruited between February and November 2012 and 24 patients were excluded from the study after enrolment because they did not report CRBD during recovery (Fig. 1) . One patient in the butylscopolamine group was excluded after randomization because of desaturation at PACU. Therefore, the data of the remaining 57 patients (29 in the control group and 28 in the butylscopolamine group) were analysed. Data on patients, surgeries, and anaesthesia are presented in Table 1 .
There was a significant difference over time between the two groups in the severity of CRBD (P¼0.001). Patients in the butylscopolamine group reported significantly less CRBD after administration of study drugs than did those in the control group at 1, 2, and 6 h after administration of study drugs ( Table 2 ). In addition, CRBD was completely relieved in five patients in the butylscopolamine group whereas all patients in the control group complained of CRBD at 6 h (P¼0.023).
There was a significant change in HR between the control and butylscopolamine groups over time (P¼0.02) whereas no difference was observed in MAP. HR in the butylscopolamine group was higher than those of the control group at 5, 10, and 20 min and 1 h after administration of the study drugs (Fig. 2) . However, there were no differences in the incidences of tachycardia (1 patient in each group) or hypertension (10 patients in the control group and 7 patients in the butylscopolamine group) between the two groups.
Significant differences were observed in the requirement for rescue analgesics (i.v. fentanyl 50 mg) between the two groups after drug administration (P,0.01, Table 3 ). Twenty-seven patients in the control group and 26 in the butylscopolamine group complained of dry mouth and no significant differences were observed between the control and butylscopolamine groups (Table 3) . Other adverse events, including facial flushing and blurred vision were not reported and two patients (one in each group) showed PONV ( Table 3) . Sedation scores were comparable between the two groups (Table 3) . 
Control group

Discussion
CRBD is a common complication in the PACU and the incidence of CRBD at 1 h after operation is reported to be 55-63% in male patients. 1 Significant predictors of CRBD are male gender and use of a urinary catheter ≥18 Fr. 10 These findings are explained by anatomical differences (the length of the urethra), but the relationship between the size of the bladder catheter and the severity of CRBD has not been investigated. 10 In this study, 16 or 18
Fr bladder catheters were used during urologic surgery and 71% of the patients (58 of 82 patients) complained of CRBD after operation. Most patients complained of a feeling of needing to void and suffered from a burning sensation at the urethra. Therefore, it is desirable to prevent or treat CRBD in male patients who undergo intraoperative bladder catheterization. Prevention and treatment of CRBD using various agents with anticholinergic property have been investigated. 1 2 4-7 Anticholinergic agents (such as tolterodine and oxybutynin) and gabapentin administered 1 h before surgery reduced the incidence and severity of CRBD. 1 2 4 5 8 However, these are oral agents and can cause adverse effects including dry mouth. 1 2 5 Tramadol is a centrally acting opioid analgesic with antimuscarinic actions, which effectively prevent CRBD when administered i.v. 7 Additionally, i.v. ketamine administration was effective for the prevention and treatment of CRBD. 6 11 However, administration of tramadol and ketamine was associated with a higher incidence of sedation compared with the control group. 6 7 11 We administered butylscopolamine 20 mg i.v., which has been used to treat abdominal cramping pain. 10 Butylscopolamine is an anticholinergic drug indicated for the treatment of GI spasm. 10 The onset of i.v. butylscopolamine is 10 min with a peak effect at 20-60 min and an elimination half-life ranging from 1 to 5 h. 10 As butylscopolamine is a quaternary ammonium derivative, it does not pass the BBB and rarely shows anticholinergic effects such as dry mouth, facial flushing, and blurred vision. 8 Transdermal scopolamine, another anticholinergic, effectively prevented bladder contractions after open prostatectomy, 12 but has been associated with a decreased salivary flow rate and mouth dryness. 13 Urgency to urinate and increased frequency of urination are symptoms of CRBD, which are similar to those of an overactive bladder. CRBD and overactive bladder result from involuntary contractions of the bladder detrusor muscle mediated by muscarinic receptors and, therefore, antimuscarinic therapy that suppresses involuntary bladder contractions has been used to treat overactive bladder.
14 Tolterodine and gabapentin are used to treat this condition. 15 -17 Butylscopolamine has a high affinity for muscarinic receptors located on the smoothmuscle cells of the GI tract and relaxes the smooth muscle. The mechanism by which butylscopolamine relieves CRBD may be explained by its antimuscarinic and spasmolytic properties and also a relaxant effect on the bladder. M2 and M3 muscarinic receptors are responsible for detrusor contraction of the bladder, 18 -20 and butylscopolamine is known to have a high affinity for human M2 and M3 muscarinic receptors expressed in Chinese hamster ovary cells. 8 Fewer rescue analgesics were required in the butylscopolamine groups than in the control group although butylscopolamine is a peripheral antimuscarinic agent without analgesic effects. In previous investigations of tramadol and gabapentin to prevent CRBD, postoperative pain and the requirement of rescue analgesics were reduced by the analgesic and anticholinergic properties of these agents. 4 7 There was no difference in the incidence of adverse effects between the butylscopolamine and control groups. Only two patients (one per group) showed postoperative nausea, probably because of prophylactic antiemetic agents administered at the end of surgery. Most patients in both groups complained of dry mouth at the PACU, which was attributable to preoperative fasting rather than anticholinergic side-effects. Other adverse effects such as facial flushing and blurred vision were not reported. As butylscopolamine rarely penetrates the BBB and enters the CNS, it did not induce anticholinergic effects. 8 A previous study with butylscopolamine also demonstrated that the incidence of adverse events was both low and similar to that of the placebo group. 21 Several limitations of the current study should be considered. I.V. butylscopolamine was clinically effective for the Table 3 The use of rescue analgesics after administration of the study drugs and adverse events. Values are presented as the number of patients (%). MOAA/S score, modified observer's assessment of alertness/sedation score: 5, respond readily to name spoken in normal tone; 4, lethargic response to name spoken in normal tone; 3, responds only after mild prodding or shaking
Control group (n529)
Butylscopolamine group (n528) P-value treatment of CRBD as an antimuscarinic agent, but an inhibitory action of butylscopolamine on the activity of the detrusor muscle has not been reported in animal or human studies. Further experiments in these areas are warranted. Secondly, a single dose of 20 mg butylscopolamine, which has been used for abdominal cramping pain, was used in this study. We did not evaluate the dose -response effect of butylscopolamine for the treatment of CRBD. Thirdly, in patients with severe CRBD despite administration of the study drug, rescue treatment of CRBD was not performed, as standard treatment of CRBD without side-effect has not been established yet. Fourthly, different sizes of urinary catheter were used in this study without standardization. The urologist decided the size of the urinary catheter during the operation depending on the possibility of catheter obstruction because of haematuria and there was no significant difference in the size of the urinary catheters between the control and butylscopolamine groups. Fifthly, various urologic surgeries with different degrees of CRBD and postoperative pain were included. Patients undergoing radical retropubic prostatectomy may complain of minor postoperative pain, but a higher incidence of CRBD whereas patients undergoing other urologic surgeries such as nephrolithotomies may suffer from more severe surgical pain than CRBD. This may cause confusion in the interpretation of the results though no significant difference regarding the type of surgery was observed between the two groups. In this study, the severity of CRBD was significantly decreased after administration of butylscopolamine 20 mg i.v. without adverse effects. Therefore, butylscopolamine seems to be an effective treatment for CRBD during the postoperative period.
